Abstract
Proteome analysis has rapidly developed in the post-genome era and is now widely accepted as a complementary technology to genetic profiling. The improvement in the technology of both two-dimensional electrophoresis (2-DE) analysis as well as quantitative iTRAQ has made proteomics a valuable and powerful tool to study human diseases. Clinical bioinformatics, emerging science combining clinical informatics, bioinformatics, medical informatics, information technology, mathematics, and omics science together, can be considered to be one of critical elements addressing clinical relevant challenges in early diagnosis, efficient therapies, and predictive prognosis of patients with disease. A combination of proteome analysis with clinical bioinformatics has been developed as a promising experimental approach for the identification of diagnostic and prognostic markers and so on, suggesting that proteome-based analysis is a promising tool for the identification of prognostic and diagnostic markers as well as for novel therapeutic targets which could be used for the treatment of diseases. The integration of proteome-based approaches with data from genomic or genetic profiling will lead to a better understanding of different diseases, which will then contribute to the direct translation of the research findings into clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, Currie I. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics. 2003;3(1):36–44.
Bonneau R. Learning biological networks: from modules to dynamics. Nat Chem Biol. 2008;4(11):658–64.
Chang PL. Clinical bioinformatics. Chang Gung Med J. 2005;28(4):201–11.
Chen H, Song Z, Qian M, Bai C, Wang X. Selection of disease-specific biomarkers by integrating inflammatory mediators with clinical informatics in AECOPD patients: a preliminary study. J Cell Mol Med. 2012;16(6):1286–97.
Dietel M, Schafer R. Systems pathology – or how to solve the complex problem of predictive pathology. Virchows Arch. 2008;453(4):309–12.
Hathout Y. Approaches to the study of the cell secretome. Expert Rev Proteomics. 2007;4(2):239–48.
Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem. 2005;51(12):2415–8.
Li X, Qian L, Bittner ML, Dougherty ER. A systems biology approach in therapeutic response study for different dosing regimens-a modeling study of drug effects on tumor growth using hybrid systems. Cancer Inform. 2012;11:41–60.
Logan JA, Kelly ME, Ayers D, Shipillis N, Baier G, Day PJ. Systems biology and modeling in neuroblastoma: practicalities and perspectives. Expert Rev Mol Diagn. 2010;10(2):131–45.
Long PM, Stradecki HM, Minturn JE, Wesley UV, Jaworski DM. Differential aminoacylase expression in neuroblastoma. Int J Cancer Journal international du cancer. 2011;129(6):1322–30.
Matharoo-Ball B, Ball G, Rees R. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches – a prostate cancer perspective. Vaccine. 2007;25 Suppl 2:B110–21.
Munshi NC, Avet-Loiseau H. Genomics in multiple myeloma. Clinical Cancer Res. 2011;17(6):1234–42.
Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol. 2006;2:52.
Nicholson RL, Welch M, Ladlow M, Spring DR. Small-molecule screening: advances in microarraying and cell-imaging technologies. ACS Chem Biol. 2007;2(1):24–30.
Parisi F, Ariyan S, Narayan D, Bacchiocchi A, Hoyt K, Cheng E, Xu F, Li P, Halaban R, Kluger Y. Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies. BMC Genomics. 2011;12:230.
Pavlou MP, Diamandis EP. The cancer cell secretome: a good source for discovering biomarkers? J Proteomics. 2010;73(10):1896–906.
Pazos F, Valencia A. Similarity of phylogenetic trees as indicator of protein-protein interaction. Protein Eng. 2001;14(9):609–14.
Qiu FM, Yu JK, Chen YD, Jin QF, Sui MH, Huang J. Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res. 2009;28:126.
Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol. 2002;9(3):505–11.
Saratsis AM, Yadavilli S, Magge S, Rood BR, Perez J, Hill DA, Hwang E, Kilburn L, Packer RJ, Nazarian J. Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid. Neuro Oncol. 2012;14(5):547–60.
Seng P, Drancourt M, Gouriet F, La Scola B, Fournier PE, Rolain JM, Raoult D. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis. 2009;49(4):543–51.
Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. J Clin Pharm Ther. 2011;36(5):614–24.
Simon R. Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer. 2003;89(9):1599–604.
Simon R. The use of genomics in clinical trial design. Clin Cancer Res. 2008;14(19):5984–93.
Sparkman OD. Review of the 48th ASMS conference on mass spectrometry and allied topics held in Long Beach, California June 11–15, 2000. J Am Soc Mass Spectrom. 2000;11(10):921.
Teitz T, Stanke JJ, Federico S, Bradley CL, Brennan R, Zhang J, Johnson MD, Sedlacik J, Inoue M, Zhang ZM, et al. Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One. 2011;6(4):e19133.
Thelen JJ, Miernyk JA. The proteomic future: where mass spectrometry should be taking us. Biochem J. 2012;444(2):169–81.
Vitucci M, Hayes DN, Miller CR. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer. 2011;104(4):545–53.
Wang X, Liotta L. Clinical bioinformatics: a new emerging science. J Clin Bioinformatics. 2011;1(1):1.
West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson Jr JA, Marks JR, Nevins JR. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A. 2001;98(20):11462–7.
Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, et al. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess. 2006;10(34):iii–iv. ix–xi, 1–204.
Xiang Y, Liu Y, Lee ML. Ultrahigh pressure liquid chromatography using elevated temperature. J Chromatogr A. 2006;1104(1–2):198–202.
Zhang Y, Skolnick J. The protein structure prediction problem could be solved using the current PDB library. Proc Natl Acad Sci U S A. 2005;102(4):1029–34.
Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol. 2012;52:505–21.
Zhou Q, Gallo JM. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J. 2011;13(1):111–20.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Wu, D., Li, H., Wang, X. (2013). Clinical Bioinformatics in Human Proteomics Research. In: Wang, X. (eds) Bioinformatics of Human Proteomics. Translational Bioinformatics, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5811-7_1
Download citation
DOI: https://doi.org/10.1007/978-94-007-5811-7_1
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-5810-0
Online ISBN: 978-94-007-5811-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)